Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases - PubMed
4 hours ago
- #Ovarian cancer
- #Folate receptor alpha
- #Endometrial tumors
- Folate receptor alpha (FRα) is a promising therapeutic target due to its high expression in tumors and rare expression in healthy tissue.
- Mirvetuximab soravtansine, an antibody-drug conjugate, has been approved for treating advanced platinum-resistant high-grade serous carcinoma (HGSC).
- The study analyzed FRα expression in 923 tubo-ovarian and endometrial tumors using standardized scoring criteria and the VENTANA FOLR1 CDx assay.
- Highest FRα expression was found in serous carcinomas: HGSC (45%), low-grade serous carcinoma (25%), endometrial serous carcinoma (11%), and serous borderline tumor (10%).
- Endometrioid and clear cell ovarian carcinomas showed rare positivity (2% and 1%, respectively).
- Other tumors examined, including mucinous ovarian tumors, sex cord-stromal tumors, and endometrial clear cell carcinomas, were negative for FRα expression.
- The study confirms FRα expression in HGSC and LGSC aligns with published data and is present in a minority of endometrial serous carcinomas.